Chris Feierabend
Impact in
- Oncology top 10%
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Drug Transport and Resistance Mechanisms
- Biochemistry top 10%
- Sulfur Compounds in Biology
Papers in
- Oncology 9
- Cancer Treatment and Pharmacology 5
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 2
-
- Cancer therapeutics and mechanisms 2
- Polyamine Metabolism and Applications 1
- 14-3-3 protein interactions 1
- Co-authors
- Dona Alberti (23 shared papers)George Wilding (22 shared papers)R Z Arzoomanian (10 shared papers)K D Tutsch (8 shared papers)Howard H. Bailey (9 shared papers)Rhoda Arzoomanian (14 shared papers)Kendra D. Tutsch (10 shared papers)Marcia Pomplun (5 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (6 papers)Journal of Clinical Oncology (5 papers)Investigational New Drugs (4 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)JNCI Journal of the National Cancer Institute (1 paper)
- Partner nations
- United StatesSpainGermany
In The Last Decade
Chris Feierabend
27 papers receiving 790 citations
Peers
Comparison fields: 5 of 78
- Oncology 279
- Biochemistry 51
- Cancer Research 86
- Toxicology 18
- Molecular Biology 308
Countries citing papers authored by Chris Feierabend
This map shows the geographic impact of Chris Feierabend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Feierabend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Feierabend more than expected).
Fields of papers citing papers by Chris Feierabend
This network shows the impact of papers produced by Chris Feierabend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Feierabend. The network helps show where Chris Feierabend may publish in the future.
Co-authors
The 25 scholars most cited alongside Chris Feierabend, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1997 | 139 | |
| 2 | 1994 | 111 | |
| 3 | 2002 | 101 | |
| 4 | Phase I clinical trial of perillyl alcohol administered daily. | 1998 | 91 |
| 5 | Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. | 2000 | 82 |
| 6 | 1993 | 46 | |
| 7 | 1997 | 44 | |
| 8 | 1998 | 33 | |
| 9 | 2004 | 25 | |
| 10 | 2003 | 21 | |
| 11 | 2001 | 16 | |
| 12 | Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. | 2002 | 16 |
| 13 | Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. | 2002 | 16 |
| 14 | A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. | 1994 | 16 |
| 15 | 2004 | 11 | |
| 16 | 1999 | 10 | |
| 17 | 2009 | 6 | |
| 18 | Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study. | 1996 | 6 |
| 19 | 1998 | 5 | |
| 20 | 1997 | 5 |
About Chris Feierabend
Chris Feierabend is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pharmacology and Surgery, having authored 27 papers that have together received 819 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Pharmacogenetics and Drug Metabolism (2 papers), Cancer therapeutics and mechanisms (2 papers), HER2/EGFR in Cancer Research (2 papers), Polyamine Metabolism and Applications (1 paper), Eicosanoids and Hypertension Pharmacology (1 paper) and 14-3-3 protein interactions (1 paper). The work is most often cited by research in Oncology (279 citations), Biochemistry (51 citations), Cancer Research (86 citations), Toxicology (18 citations) and Molecular Biology (308 citations). Chris Feierabend has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Dona Alberti, George Wilding, R Z Arzoomanian, K D Tutsch, Howard H. Bailey, Rhoda Arzoomanian, Kendra D. Tutsch, Marcia Pomplun, Gregory H. Ripple and Rebecca Marnocha. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Journal of Clinical Oncology, Investigational New Drugs, International Journal of Radiation Oncology*Biology*Physics and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.